CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C
-
Mar 29 2016
-
Source: Int J Circumpolar Health 2016; 75
[PDF-319.82 KB]
Details:
-
Alternative Title:Int J Circumpolar Health
-
Personal Author:
-
Description:Background
There have been few reports of hepatitis C virus (HCV) treatment results with interferon-based regimens in indigenous populations
Objective
To determine interferon-based treatment outcome among Alaska Native and American Indian (AN/AI) population
Design
In an outcomes study of 1,379 AN/AI persons with chronic HCV infection from 1995 through 2013, we examined treatment results of 189 persons treated with standard interferon, interferon plus ribavirin, pegylated interferon plus ribavirin and triple therapy with a protease inhibitor For individuals treated with pegylated interferon and ribavirin, the effect of patient characteristics on response was also examined
Results
Sustained virologic response (SVR) with standard interferon was 167% (3/18) and with standard interferon and ribavirin was 297% (11/37) Of 119 persons treated with pegylated interferon and ribavirin, 61 achieved SVR (513%), including 10 of 46 with genotype 1 (217%), 38 of 51 with genotype 2 (745%) and 13 of 22 with genotype 3 (591%) By multivariate analysis, SVR in the pegylated interferon group was associated with female sex (p=0002), estimated duration of infection (p=0034) and HCV genotype (p<00001) There was a high discontinuation rate due to side effects in those treated with pegylated interferon and ribavirin for genotype 1 (522%) Seven of 15 genotype 1 patients treated with pegylated interferon, ribavirin and telaprevir or boceprevir achieved SVR (467%)
Conclusions
We had success with pegylated interferon-based treatment of AN/AI people with genotypes 2 and 3 However, there were low SVR and high discontinuation rates for those with genotype 1
-
Subjects:
-
Source:
-
Pubmed ID:27029671
-
Pubmed Central ID:PMC4814572
-
Document Type:
-
Funding:
-
Place as Subject:
-
Location:
-
Volume:75
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
